Athersys, Inc., a clinical-stage biotechnology company, develops therapies in the regenerative medicine area. Its stem cell product candidate is the MultiStem cell therapy, an allogeneic stem cell product for the treatment of indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as other critical care conditions. The company was founded in 1995 and is headquartered in Cleveland, Ohio. On September 24, 2024, the voluntary petition of Athersys, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy along with its affiliates on January 5, 2024.
Name | Title | Since | Age |
|---|---|---|---|
| Z. Kasey Rosado | Interim CFO & Director | 2024 | 52 |
| James G. Shook | Scientific and Clinical Advisor | 2000 | 86 |
| C. Thomas Caskey | Scientific and Clinical Advisor | 2000 | 86 |
| Catherine Verfaillie | Scientific and Clinical Advisor | - | - |
| Michael Simons | Scientific and Clinical Advisor | - | - |
| Ira Mellman | Scientific and Clinical Advisor | - | - |
| Gilbert Clincke | Scientific and Clinical Advisor | - | - |
| Brian H. Annex | Scientific and Clinical Advisor | - | - |
| F. Xavier Pi-Sunyer | Scientific and Clinical Advisor | - | - |
| John Wagner | Scientific & Clinical Advisor | - | - |
| Jerry Silver | Scientific and Clinical Advisor | - | - |
| Larry Wechsler | Scientific and Clinical Advisor | - | - |
| Warren Sherman | Scientific and Clinical Advisor | - | 75 |
| Marc Steven Penn | Scientific and Clinical Advisor | - | - |
| Richard T. Maziarz | Scientific & Clinical Advisor | - | - |
| Hillard M. Lazarus | Scientific & Clinical Advisor | - | - |
| Robert F. Kushner | Scientific and Clinical Advisor | - | - |
| David Hess | Scientific and Clinical Advisor | - | - |